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In the context of comparative research, the World Health Organisation (WHO)
proposed to categorise the risk for alcohol-related acute and chronic harm accord-
ing to patients’ average daily alcohol consumption. OBJECTIVES: To estimate util-
ity scores associated with each category of the WHO drinking risk-level classifica-
tion in patients with alcohol dependence (AD). METHODS: We used data from
CONTROL, an observational cohort study including 143 AD patients from the Alco-
hol Treatment Center at Lausanne University Hospital, followed for 12 months.
Average daily alcohol consumption was assessed monthly using the Timeline Fol-
low-back method and patients were categorised according to the WHO drinking
risk-level classification: abstinent, low, medium, high and very high. Other mea-
sures as sociodemographic characteristics and utility scores derived from the Eu-
roQoL 5-Dimensions questionnaire (EQ-5D) were collected every three months.
Mixed models for repeated measures were used to estimate mean utility scores
associated with WHO drinking risk-level categories. RESULTS: A total of 143 pa-
tients were included and the 12-month follow-up permitting the assessment of
1318 person-months. At baseline the mean age of the patients was 44.6 (SD 11.8)
and the majority of patients was male (63.6%). Using repeated measures analysis,
utility scores decreased with increasing drinking levels, ranging from 0.80 in absti-
nent patients to 0.62 in patients with very high risk drinking level (p0.0001).
CONCLUSIONS: In this sample of patients with alcohol dependence undergoing
specialized care, utility scores estimated from the EQ-5D appeared to substantially
and consistently vary according to patients’ WHO drinking level.
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EXAMINING THE DIFFERENCES BETWEEN PATIENTS TREATED FOR MAJOR
DEPRESSIVE DISORDER COMPARED TO THOSE WHO DO NOT REALIZE THEY
HAVE MAJOR DEPRESSIVE DISORDER
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OBJECTIVES:Major Depressive Disorder (MDD) has a profound negative impact on
sufferers’ lives. This analysis sought to identify differences in patient characteris-
tics and outcomes associatedwith self-report of depression and use of prescription
treatment within a positively-screened MDD population. METHODS: Data were
taken from the US 2011 National Health and Wellness Survey (n75,000), a cross-
sectional Internet-based survey representative of US adults. Patients with MDD
were identified using the Patient Health Questionnaire (PHQ-9). Health-related
quality of life (HRQoL) was assessed with the SF-12 Health Survey (SF-12v2), and
activity impairment was measured with the Work Productivity and Activity Im-
pairment questionnaire (WPAI). Comparisons between patient groups were made
with chi-square tests for categorical variables and ANOVA for continuous
variables. RESULTS: PHQ-9 scores identifiedMDD in 6.3% of respondents (n4,720);
33.5% (n1,583) reported depression and prescription treatment, 30.0% (n1418)
reported depression without prescription treatment, and 36.4% (n1719) did not
self-report depression. Compared to those who did not self-report depression,
treated patients were more likely to have severe depression according to PHQ-9
scores (32.5% vs. 22.2%), had lower mental HRQoL (28.5 vs. 37.3), and more activity
impairment (60.5% vs. 47.4%) (ps0.001); however, fewer treated patients visited
the emergency room in the past 6 months (25.0% vs. 21.3%, p0.001). Patients who
did not report depression were more likely to have completed college (34.6% vs.
30.6%) and had higher incomes (37.6% with incomes over $50,000 vs. 32.4%), but
were less likely to have insurance (70.5% vs. 80.6%), and those with insurance were
less likely to have prescription drug coverage (60.2% vs. 74.4%) (ps0.001).
CONCLUSIONS: Patients who had MDD according to PHQ-9 but did not report de-
pression had less severe depression and a highermental QoL than treated patients,
but still had poor health outcomes. Less comprehensive insurance coverage may
be a barrier in seeking treatment.
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OBJECTIVES: The purpose of this study is to identify factors that predict whether
clientswill respond that theywere “generally satisfied”with services received from
Kentucky Community Mental Health Centers (CMHCs) in 2010. METHODS: Ken-
tucky Cabinet for Health and Family Services, Department for Behavioral Health
Developmental and Intellectual Disabilities (BHDID) conducted a survey to evalu-
ate consumers’ satisfaction with services delivered at the CMHCs in Kentucky. The
surveywas administered at outpatient clinics operated by CMHCs. The validity and
reliability of the survey were reviewed and a logistic regression model was devel-
oped using respondents’ characteristics and their responses about several aspects
of services. RESULTS: During the fiscal year 2010 (7/1/2009  6/30/2010), 117,526
adult patients visited Kentucky CMHCs and 7,029 of them participated in the sur-
vey, resulting in a 5.98% penetration rate. Logistic regression analyses show that
positive perceptions of access, quality and participation in treatment planning
significantly increase positive responses for general satisfaction by 21%, 27% and
5%, respectively. (dy/dx 0.21, 0.27 and 0.05, p0.05) Females are shown to bemore
likely to respond positively on general satisfaction (dy/dx 0.01, p0.05). Age, race
and regional characteristics (rural/urban) were not significantly related to re-
sponses to general satisfaction at the 95% confidence level. CONCLUSIONS: Re-
sponses to general satisfaction are more associated with responses to other do-
mains than respondents’ demographic characteristics. More specifically, the
domains of access, quality, and participation in treatment planning are stronger
predictors of a positive response on the “general satisfaction” question, suggesting
that more attention to those domains of service could positively influence mental
health care recipients’ responses regarding general satisfaction.
PMH48
VALIDATION OF PSPSQ MEASURING PATIENT SATISFACTION WITH
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OBJECTIVES: To assess psychometric properties of the Patient Satisfaction with
Pharmacist Services Questionnaire (PSPSQ) in a pharmacist-managed outpatient
psychiatric care clinic.METHODS: This descriptive, cross-sectional study was con-
ducted at a pharmacist-managed psychiatric care clinic in a behavioral healthcare
facility in Southern California between Nov. 2011 and Jan. 2012. Patients were
included if theywere18 years of age and able to read English. PSPSQ consists of 22
items assessed on a four point Likert scale, and hypothesized to have three do-
mains: patient-pharmacist relationship, quality of care and overall satisfaction.
This study was approved by the Institutional Review Board for exempt status.
PSPSQ has been previously tested for face and content validity and is being vali-
dated in other pharmacist managed Disease State Management clinics. Data col-
lected following patients’ visit were analyzed descriptively. Correlations were ex-
amined between age, gender, education, insurance status and patient satisfaction.
Scale reliability was assessed using Cronbach’s alpha and construct validity using
factor analysis. RESULTS: Thirty-five participants completed the survey. Mean age
of participants was 41 years, 54% were male, 37.9% were Caucasian and Hispanic
each, 81% had some college education, and 80% were covered by private health
insurance. Cronbach’s alpha of the tool was 0.971 indicating very high reliability.
After excluding two items, factor analysis yielded 19 items loading on three factors
accounting for 79.6% of the variance. Only one item loaded on a factor different
than hypothesized. The overall mean score of 3.5/4 indicated patient satisfaction
with the pharmacist services they received. Patients with private insurance
showed greater satisfaction compared to others (p0.05). CONCLUSIONS: Our re-
sults suggest that the PSPSQ can serve as a reliable and valid tool for measuring
patient satisfaction with pharmacist clinical services in a community/ambulatory
care setting. Further research is needed to confirm its utility in other pharmacy
practice settings.
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OBJECTIVES: To assess the impact of severity of autism spectrum disorders (ASD)
on caregiver burden and satisfaction with school district services.METHODS: Sur-
vey datawas collected from 301 primary caregivers of childrenwith ASD. Caregiver
burden was measured using the Caregiver Strain Questionnaire (CGSQ) and ASD
severity in childrenwasmeasured using the ChildhoodAutismRating Scale-Parent
version (CARS-P) for functional impairments and Developmental Behavior Check-
list- Parent version (DBC-P24) for behavior problems. Children with ASD were clas-
sified into high and low severity subgroups based on the scores received on CARS-P
and DBC-P24, respectively. One-way analysis of variance (ANOVA) was performed
to assess differences in caregiver burden scores and satisfaction with seven types
of school district services between high and low severity subgroups. One-way AN-
COVA was performed to determine the mediating effect of caregiver burden be-
tween ASD severity and satisfaction with school district services. RESULTS: An
overall significant effect on caregiver burden scoreswas observed for both behavior
problems (F (1,299) 55.4, p0.001) and functional impairments (F (1,299)  42.5,
p0.001) sub-groups. Higher scores were reported for the high behavior problems
(Mean8.3, S.E0.13) and the high functional impairments groups (Mean 8.4,
S.E0.15). Satisfactionwith all school district services except for occupational ther-
apy differed significantly between the severity sub-groups. Caregivers of children
with ASD in high behavior problems and high functional impairments groups re-
ported lower satisfaction with services. The ANCOVA, however, showed no signif-
icant differences in service satisfaction between the severity sub-groups suggest-
ing a mediating role of caregiver burden. CONCLUSIONS: Severity of a child’s ASD
as defined by a combination of the extent of functional impairments and behavior
problems was found to be associated with higher caregiver burden and greater
dissatisfaction with services. Clinical diagnosis of ASD severity alone may not
predict the extent of unmet school service needs.
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OBJECTIVES: To examine psychiatrists’ preferences for specific attributes of anti-
psychotics in the treatment of schizophrenia.METHODS: A discrete choice exper-
iment (DCE) was administered to psychiatrists to examine 7 attributes of antipsy-
chotics (efficacy, mode of administration, formulary access, onset of action, dosing
frequency, safety, and side effects). Psychiatrists were presented with 18 total
choices and asked to indicate which of 2 hypothetical medications they preferred.
Choices were divided among 3 profiles of patients with schizophrenia (average
patient, symptomatic nonadherent patient, and chronic nonadherent patient). De-
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scriptive statistics were reported for psychiatrists’ sociodemographic and profes-
sional characteristics. Part-worth utilities were estimated using random effects
logit models, and relative importance values were calculated for the attributes.
RESULTS:Complete datawere available from478 psychiatrists; theirmean agewas
52.1 (9.4 SD) years, and the majority were male (n326; 68.2%) and Caucasian
(n354; 74.1%). The psychiatrists had a mean of 19.0 (9.1 SD) years’ experience
practicing psychiatry. Across all patient profiles, the efficacy attribute consistently
had the highest relative importance (RI): 54.93%. Mode of administration
(RI13.51%) and formulary access (RI11.33%) also contributed notably to the psy-
chiatrists’ medication preferences. Other attributes were of more minor impor-
tance, each with RI values 10%, including onset of action (RI6.95%), dosing fre-
quency (RI: oral6.23%; injection0.94%), safety (RI4.30%), and side effects
(RI1.80%). The RI of medication attributes showed some differences across pa-
tient profiles; mode of administration increased in importance for both types of
nonadherent patients, while formulary access and safety decreased in importance.
CONCLUSIONS: The results of the DCE suggest that efficacy is the most important
factor for psychiatrists’ making medication decisions regarding the treatment of
patients with schizophrenia. The RI of efficacy does not vary by patient profile;
however, the RI of other attributes tends to vary depending on the profile of the
patient being treated.
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OBJECTIVES: Identify attributes of patients with schizophrenia taking oral antip-
sychotics who state preference for monthly injectable antipsychotic therapy.
METHODS: From a 2007-2008 survey of patients self-reporting a schizophrenia
diagnosis (N1083), respondents currently using oral antipsychotics but not inject-
ables (N984) were classified as preferring monthly injectable antipsychotic ther-
apy if they answered “very likely” or “extremely likely” on a 5-point Likert scale to,
“If you could receive your medication once a month as an injection, instead of
having to take daily tablets or liquids, how likely would you be to choose the
injection?” (N268). The comparator group consisted of those who answered “not
at all likely” or “somewhat likely” (N485). Attributes were included in a single
logistic regression model with the dependent variable indicated by the preference
for monthly injectable antipsychotic therapy. Independent variables included de-
mographics, attitudes toward disease management, previous medication and
health care resource use, and self-reported adherence, asmeasured by theMorisky
Medication Adherence Scale (MMAS). RESULTS: Current oral antipsychotic users
classified as having low adherence (MMAS3 or 4) were 1.7 times more likely to
prefer monthly injectable antipsychotic therapy (p0.03) than those more adher-
ent. Respondents aged 35-54 years were 1.8 times more likely to prefer monthly
injectable antipsychotic therapy than respondents 55 years (p0.03). Respon-
dents who stated psychiatric medication was a “very important” or “extremely
important” aspect of their life were 2.0 times more likely to prefer monthly inject-
able antipsychotic therapy (p0.01) than those attaching less importance to their
medication. CONCLUSIONS: In this survey of patients with schizophrenia, those
who viewed their psychiatric medication as important and those who reported
lower adherence were more likely to prefer once-monthly injectable antipsychotic
therapy. These insights into patient attitudes and preferences can help mental
health care professionals effectively engage in shared decision making with their
patients. Support: Janssen Scientific Affairs, LLC.
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FUNCTIONAL HEALTH AND WELL-BEING EFFICACY RESULTS FROM A PHASE III
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OBJECTIVES: Levomilnacipran (1S, 2R-milnacipran) is a potent and selective sero-
tonin and norepinephrine reuptake inhibitor (SNRI) in clinical development for the
treatment ofmajor depressive disorder (MDD). Primary and post hoc analyseswere
conducted on data from a positive Phase III trial (NCT00969709) to evaluate the
functional health and well being of patients with MDD treated with sustained
released (SR) levomilnacipran. METHODS: A double-blind, multicenter, parallel-
group, placebo-controlled, fixed-dose study in patients aged 18-65 years who met
DSM-IV-TR criteria for MDD and Montgomery-Asberg Depression Rating Scale-
Clinician Rated (MADRS-CR) score 30. Study comprised a 1-week single-blind,
placebo lead-in, 8-week double-blind treatment, and 2-week double-blind down-
taper. Patients were randomized to placebo (n175) or once-daily levomilnacipran
(n529) 40 mg, 80 mg, or 120 mg (titrated-up from an initial dose of 20 mg). Func-
tional health and well being were measured using change from baseline toWeek 8
on the SF-36v2 acute (1-week recall) health survey. Individual health dimensions,
and physical (PCS) and mental (MCS) component summary scores were compared
for levomilnacipran and placebo (ITT population) using an ANCOVA model.
RESULTS: Patients in both groups had deficits in mental-health (baseline MCS
scores: (placebo, 17.29.2; levomilnacipran, 18.28.5); baseline PCS scores (PBO:
52.611.1; LVM: 51.111.1) were slightly higher than the population norm. Follow-
ing 8 weeks of treatment, levomilnacipran patients versus placebo demonstrated
significantly greater improvement in MCS (LSMD4.41.36; p.0013) and on sev-
eral individual dimensions (General Health [2.30.69; p.0007], Vitality [2.41.05,
p.0228], Social Functioning [3.11.17; p.0086], Role Emotional [3.11.20;
p.0097], Mental Health [4.31.16; p.0003]. Nonsignificant PCS [-0.20.74;
p.8386] and other dimension score changes were noted. CONCLUSIONS: Levom-
ilnacipran patients experienced statistically significant and clinically meaningful
improvements in functional health and well being as measured by the SF-36 MCS
and associated individual dimensions. Nonsignificant changes were noted for the
PCS and associated individual dimensions. Supported by funding from Forest Lab-
oratories, Inc.
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MEASURING REAL WORLD OUTCOMES BY INCORPORATING PRO DATA
COLLECTION INTO PATIENT ACCESS SUPPORT PROGRAMS
Stevens CA
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OBJECTIVES: The current focus on the use of real world data in evaluating out-
comes, drug value and in establishing payer coverage policies requires that data be
collected post regulatory approval. The costs involved in formal late phase com-
mitments and the challenge of getting health care providers to participate in data
collection programs like registries can prove overly burdensome and rate limiting.
The objective of this study is to determine if PROmeasures can be incorporated into
patient support programs to collect data that can demonstrate value and be pre-
sented to payers. METHODS: Many product sponsors establish a no cost and toll
free program to support patients navigate their insurance benefits and obtain ac-
cess to prescribe therapy. A total of 2000 opioid addicted patients were divided into
2 groups; 1000 patients were not aligned with clinical care support to monitor
patient reported outcomes and 1000 that reported outcomes data into the patient
support program. RESULTS: Patients who received support services that allowed
for the collection of PRO’s stayed on treatment longer than those who did not have
access to report outcomes. Patients in the reporting arm stayed on therapy on
average three months longer than the patients who did not report outcomes. Pa-
tients who stayed on therapy longer did not cost payers as much as those who
came off of therapy sooner. CONCLUSIONS: Product sponsor patient support pro-
grams can serve as a valuable tool to support the reporting and collecting of PRO
data. Such programs can contain an opt-in procedure to allow patients access to
PRO tools that can help manage their disease and track treatment outcomes. Such
data can then be analyzed and reported on to demonstrate product value and cost
effectiveness through Budget Impact Modeling (BIM) comparing the cost of care of
those who do not track PRO data vs. those who do not.
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DEPRESSION FOR GENERAL POPULATION
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OBJECTIVES: The goal of this study was to examine the impact of physical pain on
depression using longitudinal survey data for general population in the United
States. METHODS: This work employed two rounds of Medical Expenditure Panel
Survey (MEPS) fromyears 2008 and 2009. Depressionwasmeasured by frequency of
feeling depressed over the last 2 weeks, scaled by 0-not at all, 1-several days, 2-
more than half the days, and 3-nearly every day. Physical pain was measured by
severity of pain scaled by 1-not at all, 2-a little bit, 3- moderately, 4-quite a bit, and
5-extremely. People older than 18, who had reported severity of depressed mood
and recent physical pain, marriage status, family size, and highest education de-
greeswere included in the study. Only round 2 and round 4 of the surveywere used
since pain questions were only asked in these two rounds. The final panel con-
tained 21,257 observations, among which 46.32% and 45.34% reported pain limited
normal work in round 2 and round 4 respectively; 28.25% and 27.26% documented
depressedmood in round 2 and 4 respectively. Ordinary Least Squares (OLS), Linear
Mixed Effect Model (LME), generalized linear model (GLM) were used to examine
the impact of pain on depression. RESULTS: Comparedwith GLM and LME, the OLS
estimates were shown upward biased. GLM and LME both suggested that individ-
uals whose physical pain deteriorated to the next level from round 2 to round 4
would present a 0.16 (p0.0001) more depressed mood (based on 0-3 scale) on
average. Individuals perceived better health status,were older, richer,married, and
employed were less depressed. CONCLUSIONS: This work utilized a national rep-
resentative longitudinal data to examine the impact of physical pain on depres-
sion. Severity of pain and some individual characteristics were found significantly
affecting the severity of depression.
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RACIAL AND ETHNIC DIFFERENCES IN ADHD IN YOUNG AND ADOLESCENT
CHILDREN: PARENTAL REPORTS IN THE MEDICAL EXPENDITURE PANEL
SURVEY 2008
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OBJECTIVES: Attention-deficit/hyperactivity disorder (ADHD) is the most common
neurobehavioral disorder characterized by developmentally inappropriate levels
of inattention andhyperactivity. Previous literature suggests that, racial and ethnic
disparities continue to exist for several medical conditions. Some studies have
shown that such differences reduce when difference in family income, health in-
surance and such sociodemographic factors are taken into account. But, it has been
also documented that such differences may accentuate for specific type of disor-
der. Aim of this study was to determine any racial and ethnic differences and
weather such differences can be explained by child’s other health condition and
sociodemographic characteristics.METHODS: A nationally representative sample
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